TrialJournal of diabetes investigation2019

Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME

Takashi Kadowaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.